Phase II trial of indicine N-oxide (INDI) in patients with advanced colorectal carcinoma.
D002986:Clinical Trials as Topic; D003110:Colonic Neoplasms / Q000188:drug therapy* / Q000473:pathology; D003497:Cyclic N-Oxides / Q000009:adverse effects / Q000627:therapeutic use*; D004334:Drug Administration Schedule; D004341:Drug Evaluation; D006801:Humans; D009503:Neutropenia / Q000139:chemically induced; D011763:Pyrrolizidine Alkaloids / Q000009:adverse effects / Q000627:therapeutic use*; D013921:Thrombocytopenia / Q000139:chemically induced
D003497:Cyclic N-Oxides; D011763:Pyrrolizidine Alkaloids; C013095:indicine-N-oxide